Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review

© 2015 International Society on Thrombosis and Haemostasis. Background: Dabigatran, a direct thrombin inhibitor, is effective for the treatment of venous thromboembolism and the prevention of stroke and systemic embolism resulting from atrial fibrillation. The most effective way of reversing the ant...

Full description

Saved in:
Bibliographic Details
Main Authors: C. Chai-Adisaksopha, C. Hillis, W. Lim, K. Boonyawat, K. Moffat, M. Crowther
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942871422&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/54789
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-54789
record_format dspace
spelling th-cmuir.6653943832-547892018-09-04T10:23:32Z Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review C. Chai-Adisaksopha C. Hillis W. Lim K. Boonyawat K. Moffat M. Crowther Medicine © 2015 International Society on Thrombosis and Haemostasis. Background: Dabigatran, a direct thrombin inhibitor, is effective for the treatment of venous thromboembolism and the prevention of stroke and systemic embolism resulting from atrial fibrillation. The most effective way of reversing the anticoagulant effect of dabigatran in patients who have bleeding complications is unknown. Objectives: To document the clinical outcomes of patients undergoing renal replacement therapy (RRT) for dabigatran-associated bleeding. Methods: We searched MEDLINE and EMBASE up to May 2015. Articles were selected if the patients presented with dabigatran-associated bleeding, underwent RRT for dabigatran removal, and reported an effect on bleeding. Results: The search yielded 22 studies representing 35 unique patient cases. The median patient age was 74.1 years (range, 56-94 years). Thirteen patients (37.1%) were female, and 32 (91.4%) patients received dabigatran for atrial fibrillation. Twenty-three patients (65.7%) underwent intermittent hemodialysis, 10 patients (28.6%) underwent continuous RRT (CRRT), and two patients underwent both intermittent hemodialysis and CRRT. Following RRT, there were significant reductions in dabigatran concentrations (P = 0.001). Rebound of the dabigatran concentration was reported in 12 (57.1%) patients following cessation of RRT. Hemostasis was reportedly achieved in 24 patients (70.6%), and 10 patients (29.4%) died because of bleeding. Conclusions: In patients with dabigatran-associated bleeding, RRT appears to be effective in reducing dabigatran concentrations, and in case reports this has been associated with a reduction in the duration and/or severity of bleeding. However, a rebound in concentrations may be seen following withdrawal of RRT, suggesting that a prolonged course of RRT may be more effective. 2018-09-04T10:23:32Z 2018-09-04T10:23:32Z 2015-01-01 Journal 15387836 15387933 2-s2.0-84942871422 10.1111/jth.13117 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942871422&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/54789
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
spellingShingle Medicine
C. Chai-Adisaksopha
C. Hillis
W. Lim
K. Boonyawat
K. Moffat
M. Crowther
Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review
description © 2015 International Society on Thrombosis and Haemostasis. Background: Dabigatran, a direct thrombin inhibitor, is effective for the treatment of venous thromboembolism and the prevention of stroke and systemic embolism resulting from atrial fibrillation. The most effective way of reversing the anticoagulant effect of dabigatran in patients who have bleeding complications is unknown. Objectives: To document the clinical outcomes of patients undergoing renal replacement therapy (RRT) for dabigatran-associated bleeding. Methods: We searched MEDLINE and EMBASE up to May 2015. Articles were selected if the patients presented with dabigatran-associated bleeding, underwent RRT for dabigatran removal, and reported an effect on bleeding. Results: The search yielded 22 studies representing 35 unique patient cases. The median patient age was 74.1 years (range, 56-94 years). Thirteen patients (37.1%) were female, and 32 (91.4%) patients received dabigatran for atrial fibrillation. Twenty-three patients (65.7%) underwent intermittent hemodialysis, 10 patients (28.6%) underwent continuous RRT (CRRT), and two patients underwent both intermittent hemodialysis and CRRT. Following RRT, there were significant reductions in dabigatran concentrations (P = 0.001). Rebound of the dabigatran concentration was reported in 12 (57.1%) patients following cessation of RRT. Hemostasis was reportedly achieved in 24 patients (70.6%), and 10 patients (29.4%) died because of bleeding. Conclusions: In patients with dabigatran-associated bleeding, RRT appears to be effective in reducing dabigatran concentrations, and in case reports this has been associated with a reduction in the duration and/or severity of bleeding. However, a rebound in concentrations may be seen following withdrawal of RRT, suggesting that a prolonged course of RRT may be more effective.
format Journal
author C. Chai-Adisaksopha
C. Hillis
W. Lim
K. Boonyawat
K. Moffat
M. Crowther
author_facet C. Chai-Adisaksopha
C. Hillis
W. Lim
K. Boonyawat
K. Moffat
M. Crowther
author_sort C. Chai-Adisaksopha
title Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review
title_short Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review
title_full Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review
title_fullStr Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review
title_full_unstemmed Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review
title_sort hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942871422&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/54789
_version_ 1681424385464860672